{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T06:39:14Z","timestamp":1773815954926,"version":"3.50.1"},"reference-count":29,"publisher":"The Journal of Rheumatology","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:sec><jats:title>Objective.<\/jats:title><jats:p>This study evaluated the effect of ixekizumab (IXE) on self-reported functioning and health in patients with radiographic axial spondyloarthritis (r-axSpA) who were either biological disease-modifying antirheumatic drug (bDMARD)\u2013na\u00efve or failed at least 1 tumor necrosis factor inhibitor (TNFi).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods.<\/jats:title><jats:p>In 2 multicenter, randomized, double-blind, placebo-controlled, and active-controlled (bDMARD-na\u00efve only) trials, patients with r-axSpA were randomly assigned to receive 80 mg of IXE [every 2 weeks (Q2W) or every 4 weeks (Q4W)], placebo (PBO), or adalimumab (ADA; bDMARD-na\u00efve only). After 16 weeks, patients who received PBO or ADA were rerandomized to receive IXE (Q2W or Q4W) up to Week 52. Functioning and health were measured by the generic 36-item Short Form Health Survey (SF-36) and the disease-specific Assessment of Spondyloarthritis international Society Health Index (ASAS HI). Societal health utility was assessed by the 5-level EuroQol-5 Dimension (EQ-5D-5L).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>At Week 16, both doses of IXE in bDMARD-na\u00efve and TNFi-experienced patients resulted in larger improvement in SF-36, ASAS HI, and EQ-5D-5L versus placebo. For SF-36, the largest improvements were seen for the domains of bodily pain, physical function, and role physical. A larger proportion of patients reaching improvement in ASAS HI \u2265 3 as well as an achievement of ASAS HI good health status was reported in patients treated with IXE. Improvements were maintained through Week 52.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion.<\/jats:title><jats:p>IXE significantly improved functioning and health as assessed by both generic and disease-specific measures, as well as societal health utility values in patients with r-axSpA, as measured by SF-36, ASAS HI, and EQ-5D-5L at Week 16, and improvements were sustained through 52 weeks.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.200093","type":"journal-article","created":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T16:21:50Z","timestamp":1594830110000},"page":"188-197","source":"Crossref","is-referenced-by-count":12,"title":["Ixekizumab Improves Functioning and Health in the Treatment of Radiographic Axial Spondyloarthritis: Week 52 Results from 2 Pivotal Studies"],"prefix":"10.3899","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5668-4497","authenticated-orcid":false,"given":"Uta","family":"Kiltz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9328-0336","authenticated-orcid":false,"given":"James Cheng-Chung","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5781-158X","authenticated-orcid":false,"given":"D\u00e9sir\u00e9e","family":"van der Heijde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3561-5932","authenticated-orcid":false,"given":"Filip","family":"van den Bosch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica A.","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annelies","family":"Boonen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6314-5336","authenticated-orcid":false,"given":"Lianne S.","family":"Gensler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theresa","family":"Hunter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hilde","family":"Carlier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoqi","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Bolce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4978-4072","authenticated-orcid":false,"given":"Vibeke","family":"Strand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9156-5095","authenticated-orcid":false,"given":"Juergen","family":"Braun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2262","published-online":{"date-parts":[[2020,7,15]]},"reference":[{"key":"2022062114101486000_48.2.188.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31591-4"},{"key":"2022062114101486000_48.2.188.2","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21621"},{"key":"2022062114101486000_48.2.188.3","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2015.13"},{"key":"2022062114101486000_48.2.188.4","doi-asserted-by":"publisher","DOI":"10.1097\/MAJ.0b013e31820f8c99"},{"key":"2022062114101486000_48.2.188.5","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1002\/acr.22831","article-title":"Global prevalence of spondyloarthritis: A systematic review and meta-regression analysis","volume":"68","author":"Stolwijk","year":"2016","journal-title":"Arthritis Care Res"},{"key":"2022062114101486000_48.2.188.6","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/RHU.0000000000000589","article-title":"Patient burden of axial spondyloarthritis","volume":"23","author":"Strand","year":"2017","journal-title":"J Clin Rheumatol"},{"key":"2022062114101486000_48.2.188.7","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21994"},{"key":"2022062114101486000_48.2.188.8","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-7-25"},{"key":"2022062114101486000_48.2.188.9","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-010-1604-2"},{"key":"2022062114101486000_48.2.188.10","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210770"},{"key":"2022062114101486000_48.2.188.11","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2016-000396"},{"key":"2022062114101486000_48.2.188.12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61134-4"},{"key":"2022062114101486000_48.2.188.13","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12670"},{"key":"2022062114101486000_48.2.188.14","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1080\/14712598.2019.1605352","article-title":"IL-17 inhibition in axial spondyloarthritis: current and future perspectives","volume":"19","author":"Torgutalp","year":"2019","journal-title":"Expert Opin Biol Ther"},{"key":"2022062114101486000_48.2.188.15","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S100940"},{"key":"2022062114101486000_48.2.188.16","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1080\/14712598.2018.1410133","article-title":"Ixekizumab: An anti-IL-17A monoclonal antibody for the treatment of psoriatic arthritis","volume":"18","author":"Toussirot","year":"2018","journal-title":"Expert Opin Biol Ther"},{"key":"2022062114101486000_48.2.188.17","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216118"},{"key":"2022062114101486000_48.2.188.18","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31946-9"},{"key":"2022062114101486000_48.2.188.19","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/art.40753","article-title":"Efficacy and safety of ixekizumab in the treatment of radiographic axial spondyloarthritis: Sixteen-week results from a phase III randomized, double-blind, placebo-controlled trial in patients with prior inadequate response to or intolerance of tumor necrosis factor inhibitors","volume":"71","author":"Deodhar","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2022062114101486000_48.2.188.20","doi-asserted-by":"publisher","DOI":"10.1097\/00007632-200012150-00008"},{"key":"2022062114101486000_48.2.188.21","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.115550"},{"key":"2022062114101486000_48.2.188.22","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203967"},{"key":"2022062114101486000_48.2.188.23","first-page":"S105","article-title":"The ASAS health index (ASAS HI) - a new tool to assess the health status of patients with spondyloarthritis","volume":"32","author":"Kiltz","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"2022062114101486000_48.2.188.24","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212076"},{"key":"2022062114101486000_48.2.188.25","doi-asserted-by":"crossref","unstructured":"Szende A , Oppe M , Devlin N , editors. EQ-5D value sets: Inventory, comparative review and user guide. Springer Netherlands; 2007.","DOI":"10.1007\/1-4020-5511-0"},{"key":"2022062114101486000_48.2.188.26","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1002\/art.39805","article-title":"Effect of secukinumab on patient-reported outcomes in patients with active ankylosing spondylitis: A phase III randomized trial (measure 1)","volume":"68","author":"Deodhar","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2022062114101486000_48.2.188.27","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.131003"},{"key":"2022062114101486000_48.2.188.28","first-page":"662","article-title":"Rapid and sustained improvement in health-related quality of life and utility for 72 weeks in patients with ankylosing spondylitis receiving etanercept","volume":"35","author":"Boonen","year":"2008","journal-title":"J Rheumatol"},{"key":"2022062114101486000_48.2.188.29","doi-asserted-by":"publisher","DOI":"10.1186\/ar2790"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.200093","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T21:11:54Z","timestamp":1655845914000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.200093"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,15]]},"references-count":29,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,2,1]]},"published-print":{"date-parts":[[2021,2]]}},"alternative-id":["10.3899\/jrheum.200093"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.200093","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,15]]}}}